Summer 2026
Designed to destroy – Targeted protein degradation
The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. Other exciting topics include the treatment of epilepsy, targeted protein degradation, and Sanofi’s way into in vivo CAR-T therapy.
One of the key topics in this summer issue is drug delivery – a particularly important issue at present, as biologics are becoming increasingly sophisticated and ease of use is becoming an ever more significant distinguishing factor when drugs are designed to treat the same conditions.
Further topics in this issue:
- Politics and the German and European investment space
- Fast-track trial approval: a way to jump the EU queue?
- Swiss biotech sector posts record revenues
- Can Sanofi buy its way into in vivo CAR-T?
- Deep Dive: Treating epilepsy beyond seizure
- Watchlist: 8 European VC firms to watch in 2026
- Technology: Targeted Protein Degradation
- Interview: Next-gen oligonucleotides to transform patient care
- Opinion: Where will AI actually move the needle in drug discovery?
- The emergence of agentic AI in lab automation
- Biopeople, Associations news and insights from SLAS, BIOTECH AUSTRIA, yebn,
- Events: Biospain, Biotech Summit Austria, BIO-Europe, ICPO Theranostic Summit
- Special: Drug Delivery
- Special: RNA technologies
